Skip to content

Evolus EOLS Current ratio

Current ratio at other companies

AbbVie logo
AbbVieABBV
0.8×0.0×

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×

Where this comes from

Calculated from Evolus’s reported figures.

Based on the most recent quarter.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's current ratio?
Evolus (EOLS) reported current ratio of 2× in Q1 2026.
How has Evolus's current ratio changed year-over-year?
Evolus's current ratio decreased by 12.8% year-over-year, from 2.3× to 2×.
What is the long-term trend for Evolus's current ratio?
Over 5 years (2020 to 2025), Evolus's current ratio has grown at a 21.8% compound annual growth rate (CAGR), from 0.7× to 1.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.